Elevated drug saliva levels suggest a "depot-like" effect in subjects treated with sublingual buprenorphine.
Cone
E J
EJ
National Institute on Drug Abuse, Addiction Research Center, Baltimore, MD 21224.
Dickerson
S L
SL
Darwin
W D
WD
Fudala
P
P
Johnson
R E
RE
D000286:Administration, Sublingual; D002047:Buprenorphine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D003692:Delayed-Action Preparations; D006801:Humans; D012463:Saliva / Q000737:chemistry*
D003692:Delayed-Action Preparations; D002047:Buprenorphine